08:41 AM EDT, 09/16/2024 (MT Newswires) -- Summit Therapeutics ( SMMT ) reported on Monday strong response rates and disease control from Phase II trials of ivonescimab in triple-negative breast cancer, metastatic microsatellite-stable colorectal cancer, and recurrent / metastatic head and neck squamous cell carcinoma.

In metastatic MSS colorectal cancer, ivonescimab with or without ligufalimab plus chemotherapy achieved an 88.2% and 81.8% overall response rate, respectively, with a disease control rate of 100% in both groups, the company said.

In triple-negative breast cancer, ivonescimab plus chemotherapy showed a 72.4% response rate and a 9.3-month median progression-free survival, while in head and neck cancer, the combination treatment resulted in a 60% response rate and 7.1-month PFS, Summit Therapeutics ( SMMT ) said.

The safety profile in all three studies was acceptable and manageable, according to the company.

Summit Therapeutics ( SMMT ) shares were up nearly 2% in recent premarket activity.

Price: 32.59, Change: +0.66, Percent Change: +2.07